> Detailanzeige
Placke, Jan-Malte
[VerfasserIn];
Kimmig, Mona
[VerfasserIn];
Griewank, Klaus
[VerfasserIn];
Herbst, Rudolf
[VerfasserIn];
Terheyden, Patrick
[VerfasserIn];
Utikal, Jochen
[VerfasserIn];
Pföhler, Claudia
[VerfasserIn];
Ulrich, Jens
[VerfasserIn];
Kreuter, Alexander
[VerfasserIn];
Mohr, Peter
[VerfasserIn];
Gutzmer, Ralf
[VerfasserIn];
Meier, Friedegund
[VerfasserIn];
Dippel, Edgar
[VerfasserIn];
Welzel, Julia
[VerfasserIn];
Engel, Daniel Robert
[VerfasserIn];
Kreft, Sophia
[VerfasserIn];
Sucker, Antje
[VerfasserIn];
Lodde, Georg
[VerfasserIn];
Krefting, Frederik
[VerfasserIn];
Stoffels, Ingo
[VerfasserIn];
Klode, Joachim
[VerfasserIn];
Roesch, Alexander
[VerfasserIn];
Zimmer, Lisa
[VerfasserIn];
Livingstone, Elisabeth
[VerfasserIn];
[...]
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
- Beteiligte: Placke, Jan-Malte [VerfasserIn]; Kimmig, Mona [VerfasserIn]; Griewank, Klaus [VerfasserIn]; Herbst, Rudolf [VerfasserIn]; Terheyden, Patrick [VerfasserIn]; Utikal, Jochen [VerfasserIn]; Pföhler, Claudia [VerfasserIn]; Ulrich, Jens [VerfasserIn]; Kreuter, Alexander [VerfasserIn]; Mohr, Peter [VerfasserIn]; Gutzmer, Ralf [VerfasserIn]; Meier, Friedegund [VerfasserIn]; Dippel, Edgar [VerfasserIn]; Welzel, Julia [VerfasserIn]; Engel, Daniel Robert [VerfasserIn]; Kreft, Sophia [VerfasserIn]; Sucker, Antje [VerfasserIn]; Lodde, Georg [VerfasserIn]; Krefting, Frederik [VerfasserIn]; Stoffels, Ingo [VerfasserIn]; Klode, Joachim [VerfasserIn]; Roesch, Alexander [VerfasserIn]; Zimmer, Lisa [VerfasserIn]; Livingstone, Elisabeth [VerfasserIn]; Hadaschik, Eva [VerfasserIn]; Becker, Jürgen C. [VerfasserIn]; Weichenthal, Michael [VerfasserIn]; Tasdogan, Alpaslan [VerfasserIn]; Schadendorf, Dirk [VerfasserIn]; Ugurel, Selma [VerfasserIn]
- Erschienen: October 2023
- Erschienen in: EBioMedicine ; 96(2023) vom: Okt., Artikel-ID 104774, Seite 1-14
- Sprache: Englisch
- DOI: 10.1016/j.ebiom.2023.104774
- ISSN: 2352-3964
- Identifikator:
- Schlagwörter: Biomarker ; Immune checkpoint inhibition ; Melanoma ; Therapy outcome ; Tumor PD-L1
- Entstehung:
-
Anmerkungen:
Online verfügbar: 4. September 2023
- Beschreibung: Background - PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma therapy. Tumor PD-L1 expression represents one of few biomarkers predicting ICI therapy outcome. The objective of the present study was to systematically investigate whether the type of tumor tissue examined for PD-L1 expression has an impact on the correlation with ICI therapy outcome. - Methods - Pre-treatment tumor tissue was collected within the prospective DeCOG cohort study ADOREG/TRIM (CA209-578; NCT05750511) between February 2014 and May 2020 from 448 consecutive patients who received PD-1-based ICI for non-resectable metastatic melanoma. The primary study endpoint was best overall response (BOR), secondary endpoints were progression-free (PFS) and overall survival (OS). All endpoints were correlated with tumor PD-L1 expression (quantified with clone 28-8; cutoff ≥5%) and stratified by tissue type. - Findings - Tumor PD-L1 was determined in 95 primary tumors (PT; 36.8% positivity), 153 skin/subcutaneous (34.0% positivity), 115 lymph node (LN; 50.4% positivity), and 85 organ (40.8% positivity) metastases. Tumor PD-L1 correlated with BOR if determined in LN (OR = 0.319; 95% CI = 0.138-0.762; P = 0.010), but not in skin/subcutaneous metastases (OR = 0.656; 95% CI = 0.311-1.341; P = 0.26). PD-L1 positivity determined on LN metastases was associated with favorable survival (PFS, HR = 0.490; 95% CI = 0.310-0.775; P = 0.002; OS, HR = 0.519; 95% CI = 0.307-0.880; P = 0.014). PD-L1 positivity determined in PT (PFS, HR = 0.757; 95% CI = 0.467-1.226; P = 0.27; OS; HR = 0.528; 95% CI = 0.305-0.913; P = 0.032) was correlated with survival to a lesser extent. No relevant survival differences were detected by PD-L1 determined in skin/subcutaneous metastases (PFS, HR = 0.825; 95% CI = 0.555-1.226; P = 0.35; OS, HR = 1.083; 95% CI = 0.698-1.681; P = 0.72). - Interpretation - For PD-1-based immunotherapy in melanoma, tumor PD-L1 determined in LN metastases was stronger correlated with therapy outcome than that assessed in PT or organ metastases. PD-L1 determined in skin/subcutaneous metastases showed no outcome correlation and therefore should be used with caution for clinical decision making. - Funding - Bristol-Myers Squibb (ADOREG/TRIM, NCT05750511); German Research Foundation (DFG; Clinician Scientist Program UMEA); Else Kröner-Fresenius-Stiftung (EKFS; Medical Scientist Academy UMESciA).
- Zugangsstatus: Freier Zugang